The FDA on May 18 approved AbbVie’s Rinvoq for the treatment of moderately to severely active Crohn’s disease in adult patients who have had an inadequate response or intolerance to at least one TNF blocker. The nod becomes the JAK inhibitor’s second approval in gastroenterology, and its seventh overall. Rinvoq will also be the first JAK inhibitor in the Crohn’s market basket. The drug was first approved in 2019 for the treatment of moderate-to-severe rheumatoid arthritis, an indication for which it currently holds covered or better status for 96% of all insured lives in the U.S. About 63% of insured lives have preferred access to Rinvoq, largely with utilization management restrictions applied. Rinvoq was AbbVie’s sixth best-selling drug worldwide in 2022, bringing in $2.52 billion in sales, according to Evaluate Pharma. Evaluate projects the JAK inhibitor will be AbbVie’s No. 2 bestseller by 2025.